Dataset Information

Rat Serum Exosome LC-MSMS(Label free)

ABSTRACT: LC-MSMS (Label free) was performed to find differential proteins in maternal rat serum exosome between 3 normal pregnant rats and 3 pregnant rats carrying fetuses with spina bifida aperta induced by all-trans retinoic acid (Sigma; 4% [wt/vol] in olive oil; 140 mg/kg body weight by gavage) at pregnant day E18 (vaginal smear found sperm after mating as E0).

INSTRUMENT(S): Q Exactive HF

ORGANISM(S): Rattus Norvegicus (rat)

TISSUE(S): Blood Plasma

SUBMITTER: Zhengwei Yuan

LAB HEAD: Zhengwei Yuan

PROVIDER: PXD023775 | Pride | 2022-10-14

REPOSITORIES: Pride

ACCESS DATA

Publications

Serum exosomal coronin 1A and dynamin 2 as neural tube defect biomarkers.

Wang Yanfu Y Ma Ling L Jia Shanshan S Liu Dan D Gu Hui H Wei Xiaowei X Ma Wei W Luo Wenting W Bai Yuzuo Y Wang Weilin W Yuan Zhengwei Z

Journal of molecular medicine (Berlin, Germany) 20220801 9

No highly specific and sensitive biomarkers have been identified for early diagnosis of neural tube defects (NTDs). In this study, we used proteomics to identify novel proteins specific for NTDs. Our findings revealed three proteins showing differential expression during fetal development. In a rat model of NTDs, we used western blotting to quantify proteins in maternal serum exosomes on gestational days E18, E16, E14, and E12, in serum on E18 and E12, in neural tubes on E18 and E12, and in feta ...[more]

PMID: 35915349

Similar Datasets

Project description:Cerebral ischemia/reperfusion injury (CI/RI), including neurological behavior deficits, cerebral infarction, blood-brain barrier (BBB) dysfunction, and neuroinflammation, et al. is a severe challenge in treatment of ischemic stroke. Traditional Chinese medicine (TCM) with the characteristics of multi-components and multi-functions for multiple targets/pathways has been historically used in the treatment of stroke and post stroke recovery in China. QiShenYiQi (QSYQ), a representative component-based Chinese medicine, is capable of reducing organ injury caused by ischemia/reperfusion via multiple mechanisms. Recently, we have previously reported that the positive action of QSYQ against the acute phase of CI/RI is partly via modulation of neuroinflammatory response. However, the effects and underlying mechanisms of QSYQ on subacute phase of CI/RI remain unknown, which are aimed to investigate in present study. The pharmacological action of QSYQ treatment on brain damage was estimated in the experimental stroke rats underwent 90 min ischemia and 8 days reperfusion by assessing the neurological and locomotor deficits, cerebral infarction, brain edema, and BBB integrity. Furthermore, we used TMT-based quantitative proteomics technology to identify significantly differentially expressed proteins following QSYQ treatment, which could give important clues for revealing the possible mechanism underlying the positive role of QSYQ in CI/RI. Besides, immunohistochemistry, western blot analysis, RT-qPCR, and rat ELISA kits were executed to further verify the accuracy of proteomics analysis results. As a consequence, we found that treatment with QSYQ (600mg/kg) for 7 days obviously improved neurological and behavioral impairment, attenuated infarct volume and brain edema, and alleviated BBB breakdown in stroke rats. Bioinformatics analysis suggested that differentially expressed protein galectin-3 mediated inflammatory response was closely related to the beneficial effect of QSYQ. Results of immunohistochemistry, western blot analysis and RT-qPCR showed that the model rats treated with QSYQ (600mg/kg) markedly downregulated the mRNA and protein expression level of galectin-3 in brain tissues compared to the untreated stroke rats. In addition, the decrease of mRNA level in brain tissues and contents in serum of TNF-α and IL-6 following QSYQ treatment were also observed. These interesting finding manifested that the effective action of QSYQ against subacute phase of CI/RI was partly via regulating galectin-3 mediated inflammatory reaction.

Dataset Information

Rat Serum Exosome LC-MSMS(Label free)

Publications

Serum exosomal coronin 1A and dynamin 2 as neural tube defect biomarkers.

Similar Datasets

OmicsDI is part of the ELIXIR infrastructure